ChemoMetec

ChemoMetec has upgraded its revenue and operating profit guidance for the 2024/25 financial year due to better-than-expected sales and order intake, supported by a stronger US dollar and optimized operating costs. The company now anticipates revenue to be between DKK 470-490 million, up from the previous DKK 460-475 million, and EBITDA to be between DKK 250-260 million, up from DKK 230-240 million. The half-year financial report is set to be released on February 5, 2025. ChemoMetec, founded in 1997 and listed on Nasdaq OMX Copenhagen, develops and markets cell counting instruments for various industries, including pharmaceuticals and biotechnology.

Invesco Ltd. has notified ChemoMetec A/S that AIM International Mutual Funds has reduced its shareholding and voting rights in ChemoMetec A/S to below 5% as of December 4, 2024, in accordance with Section 30 of the Capital Markets Act. This change means the holding is now under the 5% threshold specified in Section 38 of the Act. ChemoMetec, founded in 1997 and listed on Nasdaq OMX Copenhagen, develops and markets cell counting instruments and other measurement tools for industries such as pharmaceuticals and biotech. For further details, contact CEO Martin Helbo Behrens or CFO Kim Nicolajsen.

Invesco Ltd. has informed ChemoMetec A/S that as of December 4, 2024, it has reduced its voting rights in ChemoMetec A/S to below 5%, falling under the threshold specified in the Capital Markets Act. ChemoMetec A/S is a company that develops and markets instruments for cell counting and other measurements, serving industries such as pharmaceuticals and biotech. It was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further details, contact CEO Martin Helbo Behrens or CFO Kim Nicolajsen.

ChemoMetec has upgraded its revenue and operating profit guidance for the 2024/25 financial year following better-than-expected sales and order intake in the second quarter. The company now anticipates revenue to be in the range of DKK 460-475 million, up from the previous guidance of DKK 445-460 million, and EBITDA in the range of DKK 230-240 million, up from DKK 222-230 million. The half-year financial report for 2024/25 is set to be released on February 5, 2025. ChemoMetec, founded in 1997 and listed on Nasdaq OMX Copenhagen, develops and markets instruments for cell counting and other measurements, serving industries such as pharmaceutical, biotech, and agriculture.

ChemoMetec A/S has announced a notification regarding transactions involving its shares, conducted by individuals with managerial responsibilities or their associates, in compliance with EU Regulation no. 596/2014. The transactions pertain to Martin Glensbjerg, Vice Chair of ChemoMetec's Board of Directors, and details can be found in the attached PDF document. ChemoMetec, established in 1997 and listed on Nasdaq OMX Copenhagen, specializes in the development and marketing of cell counting instruments for various industries. For more information, contact Kim Nicolajsen, CFO, at (+45) 48 13 10 20 or visit www.chemometec.com.

ChemoMetec A/S announced that it has received a notification regarding transactions involving its shares by individuals in managerial roles or closely associated with them, as required by EU Regulation no. 596/2014. The transactions involving CEO Martin Helbo Behrens are detailed in an attached PDF document. ChemoMetec, established in 1997 and listed on Nasdaq OMX Copenhagen, develops and markets cell counting instruments and other measurement tools for various industries globally. For more details, contact Kim Nicolajsen, CFO, or visit the company’s website.

In the first quarter of the 2024/25 financial year, ChemoMetec reported a 27% increase in revenue to DKK 115.6 million, driven by higher sales of instruments, consumables, and services across regions, particularly in the USA/Canada. Operating profit (EBITDA) rose by 50% to DKK 62.1 million, with an EBITDA margin of 54%. Notable growth was seen in the sales of instruments, especially the NC-200, NC-202, XM30, and XM40 models. ChemoMetec's largest business area, LCB, saw a 29% revenue increase. On 22 October 2024, ChemoMetec acquired Ovizio Imaging Systems SA, a company specializing in cell counters for bioprocessing. The acquisition is not expected to affect the company's profit guidance, which was recently upgraded for the full year 2024/25.

ChemoMetec has completed the acquisition of Ovizio Imaging Systems SA, a Belgian company, for EUR 2,830,000. Ovizio specializes in cell counters based on holographic microscopy, used mainly in bioprocessing and cell and gene therapy. The company reported EUR 1.4 million in revenue in 2023. ChemoMetec, founded in 1997 and listed on Nasdaq OMX Copenhagen, develops and markets instruments for cell counting and other measurements, serving the pharmaceutical, biotech, and agricultural industries. For additional information, contact Martin Helbo Behrens, CEO, or Kim Nicolajsen, CFO.

ChemoMetec has submitted a binding offer to acquire 100% of Ovizio Imaging Systems SA for EUR 2,830,000. Shareholders owning more than two-thirds of Ovizio have accepted the offer, and ChemoMetec is seeking acceptance from the remaining shareholders, who are legally obliged to do so. The acquisition is expected to close within a week. After completion, ChemoMetec will begin developing Ovizio but does not anticipate any impact on its recent financial guidance. Ovizio specializes in holographic microscopy-based cell counters used in bioprocessing and cell and gene therapy, with significant revenue from consumables and service contracts. ChemoMetec, founded in 1997 and listed on Nasdaq OMX Copenhagen, provides instruments for cell counting and other measurements to various industries.

ChemoMetec has upgraded its revenue and operating profit guidance for the 2024/25 financial year following a strong first quarter with better-than-expected sales and order intake. The company now anticipates revenue in the range of DKK 445-460 million, up from the previous guidance of DKK 435-450 million, and EBITDA in the range of DKK 222-230 million, up from DKK 216-223 million. ChemoMetec's interim report for Q1 2024/25 will be released on November 7, 2024. ChemoMetec, founded in 1997 and listed on Nasdaq OMX Copenhagen, develops and markets instruments for cell counting and other measurements, serving industries such as pharmaceutical, biotech, and agriculture worldwide.